Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I agree, this was an eye opening post when many were expecting approval in Q1 2020.
Great question. Hemostyp is Patented until Oct 2029.
By then it should own 100 % of the market. Every other gauze is the absolute worst!
Including the other two gauzes that also proved superior to Surgicel in head to head trials.
Go UEEC!
Excellent observation mr. fraudster. However, I’m overflowing with optimism and will allow no neigh sayers to infect my bubble. Hemostyp to dominate the 5 billion dollar market and then grow it to 30 Billion through new product launches and superior marketing.
$$UEEC.
$29 +++
Good afternoon E. Great DD. I believe Mr. B. took possession of these shares as of Jan 1, 2020.
For the previous two years he had essentially bankrolled the company on loans out of his own pocket.
Go UEEC. Approval 2020. It’s going to be a green Christmas.
Good Morning UEEC. Hoping for PMA announcement by EOD. Look for a steady rise in pps to Friday and an acquisition announcement in the near term. $11 - $21
Anyone still think we’re within a couple weeks of approval?
Looks like Hemostyp was finally accepted for further PMA review early Dec 2020.
The “within 180 days” to Approval clock I’ve been referencing since January has now begun.
Again, I didn’t want to be right on this fact, but it is what it is:
“We recently re-engaged with the FDA regarding the original PMA submission. During a meeting which took place earlier this month, we were able to confirm that our clinical and non-clinical data and analysis were deemed satisfactory. This position was amplified recently by the acceptance for publication in the Journal of Wound Care of a peer-reviewed white paper authored by Dr. Jerry Abate and members of our human trial team that describes the impressive results of this study. At the FDA’s request we are now pursuing certain manufacturing related testing and documentation, laboratory validations which are essential to establish our Quality Controls & Standards.“
Answer in Previous post.....
The beginning. Electric cars and all.
COCOA, FL -- (MARKET WIRE) -- 05/28/09 -- United EcoEnergy Corp. (OTCBB: UEEC), a Business Development Company (BDC), incorporated in Nevada and with its principal offices located in Florida, announced that it is acquiring Epic Wound Care LLC, a Nevada Limited Liability Company which manufactures an innovative gauze to serve the wound care market. Epic Wound Care LLC manufactures and distributes its proprietary products under its own label, HymoStyp®, and its distributor's trademarks, ActCel®, ActJel(TM), and ABC Gauze(TM). The gauze is a natural product for use in any wound site where bleeding is still present. Upon contact with moisture, the gauze breaks down to form a gel-like substance that acts as a homeostatic agent to stop bleeding. Once bleeding has ceased and coagulation has occurred, the product is then rinsed away with saline solution or lukewarm water.
Epic Wound Care LLC currently has an established distribution network with a worldwide customer base, anchored by Coreva Health Science, and is expanding its marketing efforts into the US and European retail sectors. Kelly Hickel, CEO of UEEC, stated: "It is an exciting time for UEEC and our business development program. We intend to help Epic Wound Care expand its markets for the gauze in areas of personal, retail and institutional wound care management globally. The acquisition of Epic Wound Care LLC by UEEC will allow UEEC to provide the management support and funding capability to enable Epic to expand its product base and increase its revenue potential with new product offerings."
UEEC also announced that it will launch two of its portfolio investment companies in New York City simultaneously on June 3 - 4, featuring the wound care product of Epic Wound Care and the Ultimate Aero Supercar manufactured by Shelby Super Cars and currently holding the Guinness World Record title as the "Fastest Production Car in the World." Shelby's green division, SSC Green, Inc., is also the developer of the revolutionary All-Electric Scalable Powertrain, the AESP whose systems range from 200hp to 1200+hp. For more information on these products please visit www.abcgauze.com, and www.shelbysupercars.com.
The good news is that for those who believe approval is “right around the corner” and that there was a Covid delay; PMAs from the same time period as Hemostyp original application date are getting full approval presently.
In fact, Nov/Dec 2019 applications have been getting approved for months now.
Yes, of course PMA and PMA supplements are still being approved. There is no hold on PMAs.
Here’s one that was submitted around the time many believe Hemostyp was. Nov 2019:
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P190030
Floseal Hemostatic Matrix had a couple Supplements approved last week.:
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P990009S061
On a weekly comparison PMAs are coming at same rate as Last Year.
Thank You! Great clarity and transparency on your moves.
Here’s all the details if you like reading:
From last week
https://www.sec.gov/Archives/edgar/data/1096938/000147793220007002/ueec_ex102.htm
The summary I pasted is right there in the Statement of Beneficial Ownership posted yesterday.
Thom’s 11.5 million share vesting schedule:
The restricted stock unit awards vest upon performance and do not contain a conversion or exercise price. 5% of the RSU's vest upon FDA approval of the company's class III PMA, an additional 10% of the RSU's will vest upon the execution of each commercial distribution agreement for the marketing of its products up to a maximum of three such agreements and the balance will vest upon the company achieving $30 million in gross cumulative sales or a covered transaction as defined in the agreement.
A trigger event- like completing an acquisition of UEEC is the quickest route to his riches.
UEEC - FLOAT is approximately 176,000,000 By my calculations.
MoneyRD, no one offered an answer to your question. Not too surprised.
In addition to being paid through shares Thom will Receive 11.5 Million shares As RSUs.
Once these shares are vested they will be added to outstanding shares. An approximate 6% increase in total shares.
You should dig deeper into the RSU Vesting agreement with Thom. It gives great insight into companies growth objectives going forward.
Yes they are being compensated well. Should be noted Thom can be paid in stock if board chooses (which is quite likely as there are no revenues.)
He’ll be paid at a Value of 0.50 per share.
So 30,000 shares a month. Considering shares have recently traded at an average of 1.20, he’s getting $36,000 plus per month.
Note- this is educated observation not complaint or personal commentary.
That delay is due to the plant being in South Korea. Completely different situation.
The beginning. Electric cars and all.
COCOA, FL -- (MARKET WIRE) -- 05/28/09 -- United EcoEnergy Corp. (OTCBB: UEEC), a Business Development Company (BDC), incorporated in Nevada and with its principal offices located in Florida, announced that it is acquiring Epic Wound Care LLC, a Nevada Limited Liability Company which manufactures an innovative gauze to serve the wound care market. Epic Wound Care LLC manufactures and distributes its proprietary products under its own label, HymoStyp®, and its distributor's trademarks, ActCel®, ActJel(TM), and ABC Gauze(TM). The gauze is a natural product for use in any wound site where bleeding is still present. Upon contact with moisture, the gauze breaks down to form a gel-like substance that acts as a homeostatic agent to stop bleeding. Once bleeding has ceased and coagulation has occurred, the product is then rinsed away with saline solution or lukewarm water.
Epic Wound Care LLC currently has an established distribution network with a worldwide customer base, anchored by Coreva Health Science, and is expanding its marketing efforts into the US and European retail sectors. Kelly Hickel, CEO of UEEC, stated: "It is an exciting time for UEEC and our business development program. We intend to help Epic Wound Care expand its markets for the gauze in areas of personal, retail and institutional wound care management globally. The acquisition of Epic Wound Care LLC by UEEC will allow UEEC to provide the management support and funding capability to enable Epic to expand its product base and increase its revenue potential with new product offerings."
UEEC also announced that it will launch two of its portfolio investment companies in New York City simultaneously on June 3 - 4, featuring the wound care product of Epic Wound Care and the Ultimate Aero Supercar manufactured by Shelby Super Cars and currently holding the Guinness World Record title as the "Fastest Production Car in the World." Shelby's green division, SSC Green, Inc., is also the developer of the revolutionary All-Electric Scalable Powertrain, the AESP whose systems range from 200hp to 1200+hp. For more information on these products please visit www.abcgauze.com, and www.shelbysupercars.com.
Rocketman, UHP contact is actually
Phillipe Niemetz. His contact info is on the website and I suggest you reach out to him directly. My previous communication with him have produced little insight beyond what the PRs provide.
I tried to bring in Robert as an outside consultant to help piece together the jigsaw puzzle of information and dates provided over the past 5 years. Unfortunately, he is on contract in Europe With D.Brown Consultants at this time and is not returning calls or emails.
I have reached out to Robert Langdon to help understand the most recent PRs, announcements and recent IH MoneyRD posts.
I’ll follow up once he reports back.
Why do they call it Ovaltine?
The mug is round.
The jar is round.
They should call it Roundtine.
That's gold, Jerry! Gold!
I never said it would be done on the “up and up.”
Like most of my posts, I simply made an observation based on what can be quantified.
UHP had 12 months to submit the trial results to clinical trials.
They waited until the last Days of 12th month to do so.
How is that the FDAs fault? I’m not even saying it UHPs fault, it just is what it is.
I disagree and don’t mind the discussion. Keep it coming RD. Education and facts always win.
As long as you realize this is one big happily dysfunctional Family.
Complete with grumpy dads, whiny Entitled kids, rich uncles, crazy cousins and squabbling siblings. Possibly a couple peace makers. Like most Apple pie All American Families we hang in there. Keep showing up for birthday parties and reunions. Hoping if we hang stick around long enough without disowning the whole lot, one day we’ll get a piece of GRANDPA’S MONEY!
Also Band aid, the 10Q filed Nov 13 stated:
“As of the filing date of this Form 10-Q, the FDA review process, which was temporarily held up by the Covid-19 pandemic, is ongoing.“
So chances of the PMA being posted this morning were Slim to none. (Not 0 though)
That’s right, but on the positive side UHP could be signing Conditions of Approval today. Then their PMA # is issued and done deal... if you believe Hemostyp has reached that stage in the process.
I wish. But I’m on record many times stating that I believe UHP was actually awaiting application acceptance first. No sense bailing on my theory now.
I feel clearing National Library of Medicine Quality Control Oct 22 sets up for approval WITHIN 180 days from then (WITHIN 160 days now)
On the positive side I would hope for a 2020 PMA.
As always, I hope to be proven 100% wrong (reverse Hubris) on this.
I check every Monday morning hoping to see the Approval.
Thanks, similar to 10K April 2019 and earlier PR. Minus the “drive revenue and profits organically.”
“On October 25, 2018, the Company announced that, in connection with the FDA PMA Class III approval process for HemoStyp, UHP has been contacted by several medical technology companies that are active in the surgical equipment and hemostatic products sectors, and who had expressed an interest in the Company's products and business strategy. In response to these inbound contacts, and to maximize shareholder value, the Company's board of directors has determined to conduct a review of strategic alternatives, which include a potential sale of the Company, joint venture or other commercial partnership, or a standalone growth plan. To assist in this review, the Company has retained Société Générale to serve as financial advisor to the Company and it has retained the law firm of Ruskin Moscou Faltischek PC to assist in the strategic review. There can be no assurances that any specific transaction will occur as a result of the retention of these firms.”
Ha. Good one. Finally the pretend respect I’ve been striving for.
Thanks band aid. This is why they put “Expect“ approval not “will ” within 30 days.
When you spoke, did he mention me?
Oops. There’s my Hubris acting up again.
Weekends not included?
Every FDA PMA comes with conditions of approval. This is a fact. It doesn’t mean there are outstanding issues preventing approval. It is an agreement on the conditions of approval
IE. where an item may be sold etc.
Band Aid ask if UHP would know of approval before a Public Posting. I replied Yes and explained why.
UHP will know in advance, as once FDA has cleared Hemostyp for approval UHP will have to sign off on the conditions of approval to make it official.
McKesson is a distributor not a manufacturer.
There is a 0% chance they will be the buyer.
I have posted the Access Data link multiple times. Updates every Monday morning.
Sounds like some good conversations.
Who were you communicating with? What date/month did he say the application was approved for further review? Did he mention why they didn’t announce that approval? As they aren’t shy about communicating successes. Thanks for putting in the effort here.
In response to LRM - Hemostyp did not receive FDA PMA last week.
Are you looking for another extension on our gentlemen’s bet.
Recap :
Original bet oct 9th
Extended to Oct 30th
Extended to Nov 11th.
I accept those new terms. That’s it though.
Clinical Trials doesn’t announce FDA approval. You’ll want to check access data which publishes the prior weeks approvals Monday morning.
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm
So if HemoStyp is granted FDA PMA approval (Not application filing) this week it will be posted there on Monday. No exceptions. No Covid delays.
Observations aren’t roadblocks. Also, products with millions in sales aren’t really “pretenders.”